# Autonomix Medical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Autonomix Medical, Inc.). ## Overview Autonomix Medical, Inc. is a development-stage medical device company building a catheter-based platform that combines neural sensing with radiofrequency ablation. Its lead program is designed to target pain associated with pancreatic cancer through a minimally invasive transvascular approach, with the broader goal of treating other nerve-related disorders as the platform matures. The company is still pre-commercial and is focused on proof-of-concept work, clinical development, and regulatory clearance. Autonomix’s business model is centered on disposable catheter sales to hospital catheter labs rather than large capital equipment placements. ## Products & services • Disposable sensing catheter with handpiece • RF ablation catheter for peripheral nerve targets • RF energy source for catheter-based therapy • Software user interface for signal processing and activation • Transvascular sensing and ablation platform • Pre-clinical and clinical development of nerve-targeting indications - **Catheter-based sensing and ablation system** (0%) — The core platform combines diagnostic sensing with therapeutic RF ablation to identify and treat neural targets through a transvascular approach. - **Disposable catheter consumables** (70%) — Single-use sensing and ablation catheters intended to be sold to hospitals and catheter labs as recurring procedure consumables. - **Energy delivery and interface components** (20%) — RF energy source and software-enabled user interface used to power and control the catheter system. - **Clinical and regulatory development** (10%) — Research, pre-clinical testing, and regulatory work supporting first indication approval and future label expansion. - Disposable sensing catheter with handpiece - RF ablation catheter for peripheral nerve targets - RF energy source for catheter-based therapy - Software user interface for signal processing and activation - Transvascular sensing and ablation platform - Pre-clinical and clinical development of nerve-targeting indications ## Customers Autonomix’s expected customers are hospitals and hospital catheter labs that perform interventional procedures. The company specifically expects interventional radiologists to be the primary users because the platform is designed to fit familiar catheter-based workflows and require limited training. The initial clinical and commercial focus is on patients with intractable pain associated with pancreatic cancer, but the buying decision is made by healthcare providers and hospital systems rather than patients directly. Over time, the company also targets broader interventional and specialty care settings if the platform is validated for additional indications such as hypertension, chronic pain, and other nerve-related disorders. - **Hospitals and catheter labs** (primary) — Buy the disposable catheter system and related components to perform interventional procedures with minimal capital equipment needs. - **Interventional radiologists** (primary) — Primary clinical users who need a familiar catheter workflow and limited training to adopt the platform. - **Oncology and pain treatment centers** (secondary) — Would use the system for pancreatic cancer pain and other visceral pain indications if clinical validation and approvals are achieved. - **Future specialty care providers** (emerging) — Potential buyers for expanded indications such as hypertension, chronic pain, CRPS, and cardiology-related nerve targeting. - Hospitals buying disposable catheters for procedure use - Hospital catheter labs seeking minimally invasive tools - Interventional radiologists expected to be primary users - Clinical teams treating pancreatic cancer pain - Healthcare systems that prefer disposable, low-sterilization workflows - Future specialty providers in pain, cardiology, and neuromodulation ## Geography Autonomix is headquartered in Texas and also has access to a research and development facility in Pennsylvania. The company’s current operating footprint is therefore U.S.-based, with clinical, regulatory, and commercialization efforts initially centered in the United States. Its trademark portfolio extends beyond the U.S. to Australia, China, the European Union, India, Japan, Mexico, and Singapore, which supports future international expansion but does not yet indicate meaningful revenue geography. Because the company is pre-commercial, geography currently matters more for where development work is performed and where regulatory approvals are pursued than for revenue concentration. - Headquarters leased in Texas - R&D access in Pennsylvania - Initial regulatory focus in the United States - Trademark coverage in multiple international jurisdictions - No disclosed country revenue mix because the company is pre-commercial - Future expansion could extend beyond the U.S. if approvals are obtained ## Strategy Autonomix’s near-term strategy is to advance its lead catheter-based sensing and ablation platform through clinical trials and obtain regulatory clearance for its first indication. The company is concentrating first on pancreatic cancer pain because it offers a clear clinical need and a focused path to proof-of-concept. A second strategic priority is to preserve and expand intellectual property, including new U.S. patents covering controlled sympathectomy, micro-ablation, and neurological mapping. The company also needs to secure additional financing to fund development through commercialization, making capital formation a core execution priority rather than a side task. - **Complete clinical development for the first indication** (short-term) — Clinical validation is required to prove safety and efficacy and to support regulatory clearance and eventual commercialization. - **Secure additional financing** (short-term) — The company states it needs substantial additional capital to fund operations through commercialization and avoid scaling back the business plan. - **Expand and defend intellectual property** (medium-term) — Patent protection is central to differentiating the platform against much larger electrophysiology competitors. - **Broaden the platform to adjacent indications** (long-term) — A broader indication set could increase the addressable market and improve the long-term commercial value of the platform. - Advance the lead system through clinical trials - Obtain U.S. regulatory clearance for first indication - Use pancreatic cancer pain as the initial commercial entry point - Expand intellectual property protection around sensing and ablation - Preserve optionality for adjacent indications such as hypertension and pain - Raise additional capital to fund development and launch ## Risks Autonomix faces the typical risks of a development-stage medical device company, including clinical failure, regulatory delay, and the possibility that the product never reaches commercial scale. The company explicitly highlights liquidity and going-concern pressure, since it expects to need substantial additional financing to continue operations and fund commercialization. It also faces intellectual property risk because larger competitors in electrophysiology have greater resources and could challenge patents or develop competing technologies. In addition, the company depends on third-party contractors, manufacturers, and clinical partners, so supply chain disruption, quality issues, or slow adoption by healthcare professionals could materially delay progress. - **Liquidity and going-concern risk** [critical] — The company states it will need additional financing to meet obligations and execute its business plan, and may need to scale back operations if funding is unavailable. - **Clinical and regulatory risk** [high] — The lead product is still in development, and success depends on clinical trial outcomes and regulatory clearance. - **Intellectual property risk** [high] — The company must protect its sensing and ablation technology against infringement claims and competitive copying. - **Competitive pressure from larger medical device companies** [high] — Established electrophysiology players have greater resources, commercial infrastructure, and R&D budgets. - **Third-party manufacturing and contractor dependence** [medium] — Development work relies heavily on contract engineers, manufacturers, and research organizations, which can create execution and quality risk. - **Cybersecurity and data privacy risk** [medium] — The company relies on digital systems and may handle sensitive information, making it vulnerable to breaches and operational disruption. - Need for additional capital to fund operations and commercialization - Clinical trial failure or delays could prevent regulatory approval - Competition from much larger electrophysiology companies - Patent and IP challenges could weaken differentiation - Dependence on third-party manufacturers and contractors - Adoption risk if hospitals or clinicians do not embrace the workflow - Cybersecurity and data protection risks tied to digital systems and patient data ## Accounting Autonomix’s accounting profile is shaped by its development-stage status, with most spending flowing through research and development and general and administrative expense. A key judgment area is the estimation of work performed but not yet billed by contract manufacturers, engineers, and research organizations, which can materially affect period expenses and liabilities. The company also highlights valuation of equity-related instruments and warrant liability, both of which can create non-cash volatility in reported results. Because the business is pre-revenue and dependent on clinical milestones, quarterly results are likely to be uneven and heavily influenced by timing of development spend, stock-based compensation, and financing-related accounting entries. - **Unbilled contract manufacturer and research accruals** — Can shift quarterly operating losses and balance sheet accruals - **Warrant liability and equity instrument valuation** — Can materially affect net income and volatility - **Stock-based compensation** — Raises operating expenses without immediate cash outflow - **R&D capitalization versus expensing** — Affects reported losses and comparability across periods - Accruals for work performed but not yet billed by vendors - Valuation of equity-related instruments and warrant liability - Stock-based compensation affecting operating expenses - R&D expense timing tied to clinical and pre-clinical activity - Potential quarter-to-quarter volatility from financing transactions - Pre-revenue status means small changes in spend can move reported losses materially --- *Last updated: 2026-08-11T04:46:21.761850+00:00*